CD274 and non-small cell lung carcinoma: Using multicolor flow cytometry, we prospectively monitored blood immune cells from patients with advanced NSCLC undergoing therapy with PD1 inhibitors to investigate the consequences of a PD-L1/CD274 expression of monocytes and DC in peripheral blood.